Your browser doesn't support javascript.
loading
Integrating Theranostics Into Patient Care Pathways: AJR Expert Panel Narrative Review.
O'Shea, Aileen; Iravani, Amir; Saboury, Babak; Jadvar, Hossein; Catalano, Onofrio; Mahmood, Umar; Heidari, Pedram.
Afiliação
  • O'Shea A; Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, 55 Fruit St, White 427, Boston, MA 02115.
  • Iravani A; Fred Hutchinson Cancer Center, Seattle, WA.
  • Saboury B; Department of Radiology and Imaging Sciences, Clinical Center, NIH, Bethesda, MD.
  • Jadvar H; Department of Computer Science and Electrical Engineering, University of Maryland, Baltimore County, Baltimore, MD.
  • Catalano O; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA.
  • Mahmood U; Division of Nuclear Medicine and Molecular Imaging Center, Keck School of Medicine and Viterbi School of Engineering, University of Southern California, Los Angeles, CA.
  • Heidari P; Division of Abdominal Imaging, Massachusetts General Hospital, Boston, MA.
AJR Am J Roentgenol ; 220(5): 619-629, 2023 05.
Article em En | MEDLINE | ID: mdl-36321986
Theranostics describes the coupling of a diagnostic biomarker and a therapeutic agent (i.e., a theranostic pair) that have a common target in tumor cells or their microenvironment. The term is increasingly associated with in vivo nuclear medicine oncologic applications that couple diagnostic imaging by means of gamma radiation with concomitant localized high-energy particulate radiation to a tissue expressing the common target. Several theranostic pairs have been translated into clinical practice in the United States and are poised to become a mainstay of cancer treatment. The purposes of this article are to review experience with theranostics for solid-organ malignancies and to address the practical integration into care pathways of ß-emitting therapies that include somatostatin analogue radioligands for neuroendocrine tumors, PSMA-directed therapy for prostate cancer, and 131I-MIBG therapy for tumors of neural crest origin. Toxicities related to theranostics administration and indications for cessation of therapy in patients who experience adverse events are also discussed. A multidisciplinary team-based approach for identifying patients most likely to respond to these agents, determining the optimal time for therapy delivery, and managing patient care throughout the therapeutic course is critical to the success of a radiotheranostic program.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Medicina de Precisão Tipo de estudo: Guideline Limite: Humans / Male Idioma: En Revista: AJR Am J Roentgenol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Medicina de Precisão Tipo de estudo: Guideline Limite: Humans / Male Idioma: En Revista: AJR Am J Roentgenol Ano de publicação: 2023 Tipo de documento: Article